Revolutionizing Antibiotic Discovery: Engineering Cyclic Peptides for a Healthier Future.

AureoGen's Core Technologies

Genetic Engineering of NRPS Complexes:

 Cyclic peptides are produced by intricate molecular machines called Non-Ribosomal Peptide Synthetases (NRPS).

 AureoGen employs cutting-edge genetic engineering techniques to manipulate the genes that code for these enzymes. By precisely altering the genetic blueprint, they can essentially "reprogram" the NRPS to produce modified or entirely novel cyclic peptides with enhanced properties. This approach offers a powerful tool for tailoring these natural compounds to address specific therapeutic challenges.

Visual: Include a simplified diagram of an NRPS complex, highlighting the modular nature and how genetic modifications can alter the final product. This visual aid will help users understand the complexity of the technology and increase engagement.

Innovative Chemistry:

Approach: AureoGen has pioneered novel chemical approaches to modify existing cyclic peptides. These methods enable precise and efficient structural modifications, overcoming the limitations of traditional chemical synthesis methods which often involve complex and time-consuming multi-step processes. This innovative approach allows for the creation of new chemical entities (NCEs) with improved properties like potency, selectivity, and reduced side effects.

Visual: Consider a flowchart illustrating the traditional chemical modification process versus AureoGen's streamlined approach. This visual comparison will help users understand the advantages of AureoGen's technology.

Chemo-enzymatic Synthesis (CES):

Concept: This hybrid approach combines the power of chemical synthesis with the precision of enzymatic catalysis. CES utilizes specific enzymes to catalyze key steps in the synthesis of cyclic peptides, leading to faster, more efficient, and potentially more selective production compared to traditional chemical methods.

Visual: A simple diagram showing the integration of chemical synthesis steps with enzymatic reactions could be helpful. This visual representation will aid in user understanding and enhance the overall user experience.

AureoGen's Drug Development Pipeline

AureoGen is actively developing novel antibiotics to combat the growing threat of drug-resistant infections. Their pipeline focuses on two key programs:

Antifungal Program:

Lead Compound: Aureobasidin A (AbA), a potent antifungal compound with a unique mode of action.

Challenge: AbA exhibits limited activity against certain fungal pathogens, such as Aspergillus fumigatus, a major cause of invasive fungal infections.

Approach: Utilizing their advanced chemistry and genetic engineering techniques, AureoGen is developing derivatives of AbA with improved activity against a broader spectrum of fungal infections, including A. fumigatus. This research aims to provide new therapeutic options for patients suffering from life-threatening fungal infections.

Impact: Successful development of these improved antifungal agents could significantly impact patient outcomes and public health by addressing the urgent need for new treatments to combat drug-resistant fungal infections.

Antibacterial Program:

Focus: Developing novel antibiotics to combat drug-resistant bacteria, including MRSA and Gram-negative pathogens like Pseudomonas aeruginosa and Acinetobacter baumannii.

Approaches:

Polymyxin B Derivatives: Modifying the structure of Polymyxin B to reduce its toxicity while maintaining its potent antibacterial activity. This is crucial to ensure patient safety and broaden the therapeutic window of this critical class of antibiotics.

EPP Derivatives: Optimizing the pharmacokinetic properties of EPP, a novel cyclic lipopeptide with broad-spectrum activity against Gram-positive bacteria. This optimization will enhance the drug's effectiveness by ensuring it reaches and maintains therapeutic levels in the body.

Bacitracin Derivatives: Utilizing CES to generate derivatives of Bacitracin that are less toxic and more effective against drug-resistant infections. This approach aims to revive the therapeutic potential of Bacitracin by addressing its historical limitations.

Impact: These programs hold the potential to provide new therapeutic options for patients infected with drug-resistant bacteria, addressing a critical unmet medical need and improving patient outcomes.